The Newsroom

Investigations  /  04.22.2019

Shareholder Investigation of Teligent, Inc.

Teligent, Inc. (TLGT) Accused of Misleading Investors

According to the complaint for alleged violations of the Securities Exchange Act of 1934 between May 2, 2017 and November 7, 2017,  Teligent, Inc. (TLGT) attributed its revenue growth to a combination of new product launches and competitive supply chain dynamics. In particular, Teligent CEO highlighted its supposedly well-run R&D-approval-production-launch process by pointing out two approvals from the past quarter. However, this statement was misleading because Teligent failed to disclose product non-conformities in R&D and non-compliance with applicable regulations. The truth was revealed in November 2017 when Teligent disclosed disappointing Q3 2017 earnings. Teligent attributed the drop to FDA approval delays and completion as well as undefined manufacturing issues. On this news, Teligent’s share price fell $2.29 on November 7, 2017, and has continued to plummet.

Teligent, Inc. (TLGT) Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can please send us a message via the Shareholder Information form below.

Shareholder Information

  • Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

How can we help you?

CONTACT US TODAY | 1-800-350-6003 or info@robbinsarroyo.com

Tell us your concerns